Patents Assigned to Hoffmann-La Roche
  • FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES
    Publication number: 20190016792
    Abstract: Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein i) the first and the second polypeptide comprise the mutations H310A, H433A and Y436A, or ii) the first and the second polypeptide comprise the mutations L251D, L314D and L432D, or iii) the first and the second polypeptide comprise the mutations L251S, L314S and L432S.
    Type: Application
    Filed: April 6, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Tilman Schlothauer
  • B-CELL CULTIVATION METHOD
    Publication number: 20190017022
    Abstract: Herein is reported a method for co-cultivating one or more B-cells comprising the step of incubating the one or more B-cells with EL4-B5 cells, whereby the EL4-B5 cells have been obtained/are from a cultivation of EL4-B5 cells that has a cell density of from 600,000 cells/ml up to 1,500,000 cells/ml.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sonja Offner, Friederike Jung
  • INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES
    Publication number: 20190016719
    Abstract: The present invention is concerned with indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula I wherein Ar1, A2, R1, R2, R3, X and n are as described herein and pharmaceutically acceptable salts thereof for treatment of central nervous system disorders
    Type: Application
    Filed: August 9, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans Hilpert, Sabine Kolczewski, Anja Limberg, Theodor Stoll
  • TRIMERIC COSTIMULATORY TNF FAMILY LIGAND-CONTAINING ANTIGEN BINDING MOLECULES
    Publication number: 20190016771
    Abstract: The invention relates to novel trimeric costimulatory TNF family ligand-containing antigen binding molecules comprising three fusion polypeptides, each of the three fusion polypeptides comprising (a) an ectodomain of a costimulatory TNF family ligand selected from the group consisting of 4-1BBL, OX40L and GITRL or fragments thereof, (b) a trimerization domain, in particular a trimerization domain derived from human cartilage matrix protein (huCMP) of SEQ ID NO:1, and (c) a moiety capable of specific binding to a target cell antigen, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Pablo Umana
  • METHOD FOR DETERMINING THE IN VIVO INTERACTION MODE
    Publication number: 20190016827
    Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
    Type: Application
    Filed: June 8, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg MOELLEKEN, Michael MOLHOJ, Christian GASSNER, Manuel ENDESFELDER, Joerg-Thomas REGULA
  • FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES
    Publication number: 20190016828
    Abstract: Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein i) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations H310A, H433A and Y436A, or ii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251D, L314D and L432D, or iii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251S, L314S and L432S.
    Type: Application
    Filed: April 6, 2018
    Publication date: January 17, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alexander Skolaut, Tilman Schlothauer
  • THREE-STEP ACID DISSOCIATION ENZYME LINKED IMMUNOSORBENT (TADELIS) ASSAY
    Publication number: 20190011440
    Abstract: Herein is reported a method for determining in a sample the (total, i.e. binding competent) amount of a ligand of a ligand-binding protein (therapeutic) comprising the following steps in the following order: subjecting the sample to an acid treatment, forming in solution a non-covalent complex comprising i) an anti-ligand antibody, ii) the ligand, and iii) labelled ligand-binding protein, by adding anti-ligand antibody and labelled ligand-binding protein to the sample, and determining the amount of the complex and thereby determining the amount of the ligand of the ligand-binding protein.
    Type: Application
    Filed: June 15, 2018
    Publication date: January 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Gregor JORDAN, Roland STAACK
  • Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5.6.8.8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
    Publication number: 20190010155
    Abstract: The present invention relates to a process for synthesizing a compound of formula (I), R1 is phenyl, which is unsubstituted or substituted with one, two or three substituents independently selected from halogen and C1-6alkyl; R2 is C1-6alkyl; R3 is —CxH2x—; x is 1, 2, 3, 4, 5, 6 or 7; or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating to hepatitis B infection or a disease caused by hepatitis B infection.
    Type: Application
    Filed: August 20, 2018
    Publication date: January 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Junli Chen
  • BRIDGED PIPERIDINE DERIVATIVES
    Publication number: 20190010156
    Abstract: The present invention relates to a compound of formula wherein HetAr is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, —CH2—C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n=2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Application
    Filed: June 8, 2018
    Publication date: January 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Hasane RATNI, Karlheinz BAUMANN, Guido GALLEY, Georg JAESCHKE, Roland JAKOB-ROETNE, Anja LIMBERG, Werner NEIDHART, Rosa Maria RODRIGUEZ-SARMIENTO
  • MORPHOLINE DERIVATIVE
    Publication number: 20190010148
    Abstract: The present invention relates to a compound of formula and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido Galley, Marius Hoener, Roger Norcross, Philippe Pflieger
  • Piperidine derivatives
    Patent number: 10172843
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 8, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Haap, Holger Kuehne, Harald Mauser
  • Measuring vial seal forces
    Patent number: 10175128
    Abstract: The invention deals with a measuring apparatus (1) comprising a body (11) with an interior (114) and an opening for accessing the interior (114) from outside the body (11), a rigid plunger (12) having an edge (1212) being identically shaped as an edge of a opening of a target vial, and a force sensor (13). The rigid plunger (12) extends though the opening of the body (11) into the interior (114) of the body (11). The edge (1212) of the rigid plunger (12) is arranged outside the body (11). The force sensor (13) is arranged in the interior (114) of the body (11). The rigid plunger (12) is movable relative to the body (11) and is coupled to the force sensor (13). The apparatus (1) can be used for measuring a force acting on the edge of the opening of the target vial for optimizing the adjustment of a vial closure facility.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 8, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Martin Vogt, Jean-Pierre Büttiker, Roman Mathäs, Holger Röhl
  • Cryogenic container
    Patent number: 10174985
    Abstract: The invention relates to a cryogenic container for storing and/or transporting a medium, in particular a biochemical and/or medical product. The cryogenic container comprises at least one primary container, which has at least one flexible film bag. The flexible film bag is designed to receive the medium. The cryogenic container furthermore comprises at least one secondary container, which at least partially surrounds the primary container and is preferably at least partially flexible. The secondary container has at least one opening for insertion of the primary container. The secondary container furthermore has at least one preferably at least partially flexible outer sleeve. The secondary container furthermore has at least one heat exchanger space, which is arranged between the outer sleeve and the flexible film bag and receives at least one fluid heat exchange medium.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: January 8, 2019
    Assignee: HOFFMANN LA-ROCHE, INC.
    Inventors: Theo Arnitz, Carsten Liebig
  • RECOMBINANT PRODUCTION METHOD
    Publication number: 20190002947
    Abstract: Herein is reported a method for the recombinant production of a polypeptide in a eukaryotic cell comprising the steps of (i) cultivating a eukaryotic cell comprising a nucleic acid encoding the polypeptide in a cultivation medium comprising a compound selected from the group consisting of trans-2-methyl 2-pentenoic acid, the broad-spectrum HDAC inhibitor Quisinostat, and the subtype-specific HDAC inhibitor Romidepsin, and (ii) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide in a eukaryotic cell.
    Type: Application
    Filed: June 11, 2018
    Publication date: January 3, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Tobias Killian, Markus Neubauer
  • METHOD FOR SELECTION AND PRODUCTION OF TAILOR-MADE HIGHLY SELECTIVE AND MULTI-SPECIFIC TARGETING ENTITIES CONTAINING AT LEAST TWO DIFFERENT BINDING ENTITIES AND USES THEREOF
    Publication number: 20190002570
    Abstract: Herein is reported a method for producing a bispecific antibody comprising the step of incubating (i) an antibody Fab fragment or a scFv antibody comprising within the 20 C-terminal amino acid residues the amino acid sequence LPX1TG (SEQ ID NO: 01), (ii) a one-armed antibody comprising a full length antibody heavy chain, a full length antibody light chain, and an Fc-heavy chain, whereby the full length antibody heavy chain and the full length antibody light chain are cognate antibody chains that thereof forms an antigen binding site, whereby the full length antibody heavy chain and the Fc-heavy chain are covalently linked to each other via one or more disulfide bonds forming an antibody hinge region, and whereby the Fc-heavy chain has an oligoglycine amino acid sequence at its N-terminus, and (iii) a Sortase A enzyme.
    Type: Application
    Filed: September 17, 2018
    Publication date: January 3, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sebastian FENN, Erhard KOPETZKI, Georg TIEFENTHALER
  • Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
    Patent number: 10168326
    Abstract: Herein is reported an enzyme linked immunosorbent assay for the detection of anti-drug antibodies against a drug antibody in a sample comprising a capture drug antibody and a tracer drug antibody, wherein the capture drug antibody and the tracer drug antibody are employed in a concentration of 0.5 ?g/ml or more, the sample is incubated simultaneously with the capture drug antibody and the tracer drug antibody for 1 to 24 hours, the capture drug antibody and the tracer drug antibody are derivatized via a single lysine residue, the sample comprises 10% serum, and oligomeric human IgG is added to the sample prior to the incubation with the capture drug antibody and the tracer drug antibody.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 1, 2019
    Assignee: F. HOFFMANN-LA ROCHE INC.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel
  • TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS
    Publication number: 20180371016
    Abstract: The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R3, R8, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Benoit Hornsperger, Roberto Iacone, Hans P. Maerki, Peter Mohr, Michael Reutlinger
  • Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
    Publication number: 20180370969
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Buyu Kou, Xianfeng Lin, Hong Shen, Houguang Shi, Shixiang Yan, Weixing Zhang, Zhisen Zhang, Mingwei Zhou, Wei Zhu
  • MEDICAL DELIVERY DEVICE
    Publication number: 20180369492
    Abstract: A medical delivery device (1; 10) comprises a rod element (3; 30), a dosage member (6; 60) and a lock mechanism. The rod element (3; 30) has a stem (31; 310) with a longitudinal axis (38; 380), a distal end and a proximal end. The dosage member (6; 60) comprises a delivery orifice (62; 620) and a chamber body (61; 610) with a distal end, a proximal end and a hollow interior. The stem (31; 310) of the rod element (3; 30) extends into the interior of the chamber body (61; 610) of the dosage member (6; 60) and the delivery orifice (62; 620) is arranged adjacent to the proximal end of the stem (31; 310) of the rod element (3; 30).
    Type: Application
    Filed: December 13, 2016
    Publication date: December 27, 2018
    Applicant: HOFFMANN-LA ROCHE INC
    Inventors: Maxime GAILLOT, Roberta LEAH, Declan REILLY, Mark Digby TEUCHER, Paul Graham HAYTON, Jonathan Paul RIDLEY, James Robert COOP
  • NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS
    Publication number: 20180371015
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 4, 2018
    Publication date: December 27, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hans P. Maerki, Benoit Hornsperger, Peter Mohr, Michael Reutlinger, Roberto Iacone